Article in Pharmaceutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
5 citing papers in PubMed, 5 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
16 authors at 7 institutions in 2 countries.
Andrea BagánLaboratory of Medicinal Chemistry (Associated Unit to CSIC), Department of Pharmacology, Toxicology and Medicinal Chemistry, Faculty of Pharmacy and Food Sciences, Institute of Biomedicine (IBUB), University of Barcelona, Av. Joan XXIII, 27-31, 08028 Barcelona, Spain.
Sergio Rodriguez-ArévaloLaboratory of Medicinal Chemistry (Associated Unit to CSIC), Department of Pharmacology, Toxicology and Medicinal Chemistry, Faculty of Pharmacy and Food Sciences, Institute of Biomedicine (IBUB), University of Barcelona, Av. Joan XXIII, 27-31, 08028 Barcelona, Spain.
Teresa Taboada-JaraPharmacology Section, Toxicology and Medicinal Chemistry, Faculty of Pharmacy and Food Sciences, Institut de Neurociències, University of Barcelona, Av. Joan XXIII, 27-31, 08028 Barcelona, Spain.ORCID 0000-0002-9666-333X
Christian Griñán-FerréPharmacology Section, Toxicology and Medicinal Chemistry, Faculty of Pharmacy and Food Sciences, Institut de Neurociències, University of Barcelona, Av. Joan XXIII, 27-31, 08028 Barcelona, Spain.ORCID 0000-0002-5424-9130
Mercè PallàsPharmacology Section, Toxicology and Medicinal Chemistry, Faculty of Pharmacy and Food Sciences, Institut de Neurociències, University of Barcelona, Av. Joan XXIII, 27-31, 08028 Barcelona, Spain.ORCID 0000-0003-3095-4254
Iria Brocos-MosqueraDepartment of Pharmacology, University of the Basque Country, UPV/EHU, 48940 Leioa, Spain.
Luis F CalladoDepartment of Pharmacology, University of the Basque Country, UPV/EHU, 48940 Leioa, Spain.ORCID 0000-0001-9941-012X
José A Morales-GarcíaDepartment of Cell Biology, School of Medicine, Complutense University (UCM), 28040 Madrid, Spain.ORCID 0000-0001-9008-0056
Belén PérezDepartment of Pharmacology, Therapeutic and Toxicology, Autonomous University of Barcelona, 08193 Cerdanyola, Spain.ORCID 0000-0001-5801-1704
Caridad DiazFundación MEDINA Centro de Excelencia en Investigación de Medicamentos Innovadores en Andalucía, Avda. del Conocimiento 34, 18016 Armilla, Spain.ORCID 0000-0003-1240-0143
Rosario Fernández-GodinoFundación MEDINA Centro de Excelencia en Investigación de Medicamentos Innovadores en Andalucía, Avda. del Conocimiento 34, 18016 Armilla, Spain.ORCID 0000-0002-8831-7189
Olga GenilloudFundación MEDINA Centro de Excelencia en Investigación de Medicamentos Innovadores en Andalucía, Avda. del Conocimiento 34, 18016 Armilla, Spain.ORCID 0000-0002-4202-1219
Milan BeljkasDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Belgrade, Vojvode Stepe 450, 11221 Belgrade, Serbia.
Slavica OljacicDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Belgrade, Vojvode Stepe 450, 11221 Belgrade, Serbia.
Katarina NikolicDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Belgrade, Vojvode Stepe 450, 11221 Belgrade, Serbia.ORCID 0000-0002-3656-9245
Carmen EscolanoLaboratory of Medicinal Chemistry (Associated Unit to CSIC), Department of Pharmacology, Toxicology and Medicinal Chemistry, Faculty of Pharmacy and Food Sciences, Institute of Biomedicine (IBUB), University of Barcelona, Av. Joan XXIII, 27-31, 08028 Barcelona, Spain.ORCID 0000-0002-9117-8239
Universitat de Barcelona · ESFundación Medina · ESUniversity of Belgrade · RSInstituto de Salud Carlos III · ESUniversity of the Basque Country · ESUniversidad Complutense de Madrid · ESUniversitat Autònoma de Barcelona · ES
Funding
Basque Government IT-1211-19 and 1512-22European Union NextGeneration and UCM-Santander PR44/21-29931Generalitat de Catalunya 2021 SGR 00357 and PDC2022-133441-I00 (MCIN/AEI/ 10.13039/501100011033Ministerio de Ciencia, Innovación y Universidades PID2019-107991RB-I00, PID2022-139180OB-I00
6 · The paper itself
Abstract
Humanity is facing a vast prevalence of neurodegenerative diseases, with Alzheimer's disease (AD) being the most dominant, without efficacious drugs, and with only a few therapeutic targets identified. In this scenario, we aim to find molecular entities that modulate imidazoline I
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Preclinical Evaluation of an Imidazole-Linked Heterocycle for Alzheimer's Disease. · full record | OpenQuestion